Intervention News

Most patients with severe chronic limb-threatening ischemia treated with a transcatheter deep venous arterialization system achieved limb salvage at 12 months, according to new data from the PROMISE II trial.

SAN FRANCISCO — Among patients with severe aortic stenosis and small aortic annuli, treatment with transcatheter or surgical aortic valve replacement yielded similar early and late hemodynamic and clinical outcomes in the VIVA trial.

As millennial and older physicians can verify, the path to becoming a physician is long and arduous, filled with years of rigorous education, exams and residency training.

SAN FRANCISCO — A new pooled analysis showed a maintained BP-lowering effect with fewer added medications after treatment with an ultrasound renal denervation system compared with a sham procedure, a speaker reported at TCT 2023.

SAN FRANCISCO — Among patients treated for drug-eluting in-stent restenosis, the revascularization rate at 10 years was high, according to the results of a post hoc analysis of the ISAR-DESIRE 3 trial presented at TCT 2023.

SAN FRANCISCO — Data show a novel transcatheter mitral valve edge-to-edge repair system was associated with a sustained reduction in mitral regurgitation plus functional and quality-of-life gains for patients at prohibitive surgical risk.

SAN FRANCISCO — Transcatheter tricuspid valve replacement was feasible and had a lower-than-expected rate of safety events, according to an analysis of the first 150 patients in the TRISCEND II pivotal trial.

SAN FRANCISCO — A biodegradable polymer sirolimus-eluting stent remained superior to a durable polymer everolimus-eluting stent for treating STEMI at 5 years, a difference driven by lower rates of ischemia-driven repeat revascularizations.

SAN FRANCISCO — In a real-world population of patients with ACS or chronic coronary syndrome, a strategy guided by instantaneous wave-free ratio was similarly safe as one guided by fractional flow reserve at 5 years, data show.

SAN FRANCISCO — A paclitaxel-coated balloon was superior to conventional balloon angioplasty for treatment of coronary in-stent restenosis, according to the results of the AGENT IDE trial presented at TCT 2023.